Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 100,220,040
  • Shares Outstanding, K 1,296,340
  • Annual Sales, $ 26,107 M
  • Annual Income, $ 4,628 M
  • 36-Month Beta 1.03
  • Price/Sales 3.83
  • Price/Cash Flow 7.97
  • Price/Book 4.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 1.54
  • Number of Estimates 8
  • High Estimate 1.71
  • Low Estimate 1.46
  • Prior Year 2.23
  • Growth Rate Est. (year over year) -30.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.84 +1.94%
on 07/30/18
79.04 -2.19%
on 07/26/18
-0.07 (-0.09%)
since 07/13/18
3-Month
66.64 +16.01%
on 05/15/18
79.04 -2.19%
on 07/26/18
+10.26 (+15.30%)
since 05/14/18
52-Week
64.27 +20.29%
on 05/03/18
89.54 -13.66%
on 01/29/18
+4.50 (+6.18%)
since 08/14/17

Most Recent Stories

More News
Gilead Sciences Announces Executive Promotions

--- Diana Brainard, MD, Promoted to Senior Vice President, HIV and Emerging Viral Infections -

GILD : 77.31 (+0.18%)
Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit

Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.

BAYRY : 23.7700 (+0.78%)
VRTX : 175.93 (+0.50%)
GILD : 77.31 (+0.18%)
SGEN : 74.63 (+1.12%)
AHF Files Petition for Review of Gilead AIDS Drug Patent Case with U.S. Supreme Court

--In July 2016, the US District Court for the Northern District of California granted Motion to Dismiss by Gilead; however, the Court's order suggested that the case was ripe for reconsideration by higher...

GILD : 77.31 (+0.18%)
Shire, Shionogi File NDA for Intuniv for Adults in Japan

Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

JNJ : 129.50 (-0.55%)
SHPG : 169.13 (-0.35%)
GILD : 77.31 (+0.18%)
PFE : 40.71 (-0.25%)
Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech

Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.

CELG : 92.71 (+0.80%)
LGND : 249.11 (+0.61%)
ILMN : 330.17 (+0.88%)
GILD : 77.31 (+0.18%)
Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic

Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

MDCO : 39.88 (+2.92%)
ALNY : 93.18 (+2.45%)
GILD : 77.31 (+0.18%)
SNY : 41.30 (-0.51%)
Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.

FOLD : 13.92 (-2.73%)
SHPG : 169.13 (-0.35%)
GILD : 77.31 (+0.18%)
SNY : 41.30 (-0.51%)
Biotech ETFs in Focus on String of Q2 Earnings Beat

Biotech ETFs draw attention post impressive Q2 results.

IBB : 117.21 (+0.56%)
FBT : 151.07 (+0.77%)
BBH : 129.98 (+0.55%)
IEIH : 26.26 (-0.23%)
GILD : 77.31 (+0.18%)
AMGN : 195.76 (+0.08%)
ALXN : 119.68 (+1.11%)
BIIB : 343.63 (+0.83%)
Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales

Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.

ILMN : 330.17 (+0.88%)
PBYI : 44.85 (+2.40%)
GILD : 77.31 (+0.18%)
RHHBY : 30.2100 (+1.05%)
Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat

Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.

AGEN : 1.79 (+2.29%)
MRK : 66.46 (-0.39%)
INCY : 66.45 (+2.44%)
GILD : 77.31 (+0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade GILD with:

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 78.12
1st Resistance Point 77.72
Last Price 77.31
1st Support Level 77.01
2nd Support Level 76.70

See More

52-Week High 89.54
Fibonacci 61.8% 79.89
Last Price 77.31
Fibonacci 50% 76.90
Fibonacci 38.2% 73.92
52-Week Low 64.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar